Novartis AG (NVS)

86.60
0.67 0.78
NYSE : Health Technology
Prev Close 85.93
Open 86.72
Day Low/High 86.52 / 87.18
52 Wk Low/High 74.97 / 96.31
Volume 1.12M
Avg Volume 2.01M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 216.70B
EPS 5.50
P/E Ratio 15.97
Div & Yield 1.84 (2.15%)

Latest News

Weekly Roundup

A volatile week ends with heightened expectations for at least one more rate cut from the Fed.

We Rallied, but the Stats Weren't So Hot

Breadth was crummy, the Russell lagged and the number of stocks making new lows on a 10-day moving average shows no sign of turning down yet.

September ADP Employment Report Missed Expectations

The ADP numbers... are beginning to show signs of a slowdown as employers grow more cautious when it comes to hiring activity.

Adding to a Pharmaceutical Name and Upgrading a Position

With the market expected to continue Tuesday's weak ISM PMI-driven woes, we are in position to do some buying at newly discounted prices.

Weekly Roundup

Markets buffeted by impeachment turmoil and shift away from high-multiple growth names.

Video: Jim's Daily Rundown for Thursday

Jim talks about his interview with Twilio CEO Jeff Lawson, Facebook amid the DoJ's antitrust probe and answers a club member's question!

Amgen Looks Attractive After Its Recent Pullback

Amgen Looks Attractive After Its Recent Pullback

Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.

Weekly Roundup

Markets traded mostly flat this week in spite of Saudi oil attacks, and a Fed rate cut, only turning sour on Friday on signs of renewed U.S. trade tensions with China.

Adding to a Pharmaceutical Position

We want to nibble on Novartis, which is barely reacting to company-specific positive news.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Novartis, Home Depot, and more!

Stay on Top of Your Game: Cramer's 'Mad Money' Recap (Friday 9/13/19)

Stay on Top of Your Game: Cramer's 'Mad Money' Recap (Friday 9/13/19)

Jim Cramer says investors need to stay vigilant, despite recent market gains. He's got your game plan for next week.

Trex, Enphase Energy, Alcon: 'Mad Money' Lightning Round

Trex, Enphase Energy, Alcon: 'Mad Money' Lightning Round

Jim Cramer takes a look at Trex, Enphase Energy, Alcon, Rite Aid, Tallgrass Energy and more.

Markets Have a Strong Week on Sector Rotation, Reviving Chip Stocks

Easing trade tensions and steepening yield curve add to bulls' optimism.

Adding to a Pharmaceutical Name While Taking Gains in a Semi

We will buy more Novartis shares and trim our Lam Research position.

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Tech Stocks Lag, Health Care Shakes Up and Apple's in TV

Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.

Two Tuesday Buys

We will add to our Novartis and Twilio positions this morning.

Last Week's Portfolio Changes

We initiated a new position and downgraded another last week.

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.

ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG - NVS

ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Weekly Roundup

Stocks fell on manufacturing worries, but snapped back by the end of the week on renewed hopes for easing U.S.- China trade tensions.

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Jim Cramer says we got good news on trade talks, and strong economic and employment data, all of which add up to a rally that defies recession talk.

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Jim Cramer weighs in on Beyond Meat, Yum! Brands, Netflix, Starwood Property Trust, and GW Pharmaceuticals.

Catalyst Events to Watch in Amgen and Novartis Pipelines

The pipeline is key for pharmaceutical companies.

Video: Jim's Daily Rundown for Thursday

Jim discusses his interview with Palo Alto Networks CEO Nikesh Arora, the CVS Health-Aetna merger settlement approval, Goldman Sachs and the Apple card, Novartis and more!

Initiating a Pharmaceutical Name and a Small Retail Trim

We are bringing Novartis out of the bullpen and into the portfolio.

Stocks to Watch on Volatility

A menu of stocks and associated price levels where we think a bit of nibbling and small buying is worth doing.

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG ("Novartis" or the "Company") (NYSE: NVS) investors concerning the Company and its officers' possible violations of federal securities laws.

TheStreet Quant Rating: A- (Buy)